Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06065462 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
A Phase 1 study of Ovarian Clear Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT06065462 is a Phase 1 study of Ovarian Clear Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants, below the 134-participant average among 4 other Ovarian Clear Cell Carcinoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06065462, a Phase 1 study of Ovarian Clear Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma
Conditions Studied
Interventions
- DRUG Dostarlimab
- DRUG LB-100
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06065462
The ClinicalTrials.gov registry entry for NCT06065462 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 4 other Ovarian Clear Cell Carcinoma trials with a reported enrollment target (84% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Clear Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Dostarlimab is the first listed.
NCT06065462 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06065462 about?
NCT06065462 is a clinical study titled "Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100". To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma
What is the current status of trial NCT06065462?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-11-10. Estimated completion is 2027-10-01.
What conditions does trial NCT06065462 study?
This clinical trial studies the following conditions: Ovarian Clear Cell Carcinoma.
What interventions are being tested in trial NCT06065462?
The interventions under investigation include: Dostarlimab (DRUG), LB-100 (DRUG).
Who is sponsoring clinical trial NCT06065462?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06065462 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Clear Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RECRUITING · Phase 1
-
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RECRUITING · Phase 3
-
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.